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Abstract
Spirochetes belonging to the Borrelia (B.) burgdorferi sensu lato complex differ in their resistance to complement-mediated
killing, particularly in regard to human serum. In the present study, we elucidate the serum and complement susceptibility
of B. valaisiana, a genospecies with the potential to cause Lyme disease in Europe as well as in Asia. Among the investigated
isolates, growth of ZWU3 Ny3 was not affected while growth of VS116 and Bv9 was strongly inhibited in the presence of
50% human serum. Analyzing complement activation, complement components C3, C4 and C6 were deposited on the
surface of isolates VS116 and Bv9, and similarly the membrane attack complex was formed on their surface. In contrast, no
surface-deposited components and no aberrations in cell morphology were detected for serum-resistant ZWU3 Ny3. While
further investigating the protective role of bound complement regulators in mediating complement resistance, we
discovered that none of the B. valaisiana isolates analyzed bound complement regulators Factor H, Factor H-like protein 1,
C4b binding protein or C1 esterase inhibitor. In addition, B. valaisiana also lacked intrinsic proteolytic activity to degrade
complement components C3, C3b, C4, C4b, and C5. Taken together, these findings suggest that certain B. valaisiana isolates
differ in their capability to resist complement-mediating killing by human serum. The molecular mechanism utilized by B.
valaisiana to inhibit bacteriolysis appears not to involve binding of the key host complement regulators of the alternative,
classical, and lectin pathways as already known for serum-resistant Lyme disease or relapsing fever borreliae.
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Introduction
Lyme disease, the most prevalent vector-borne anthropozoo-
nosis in Europe and North America is caused by spirochetes
belonging to the Borrelia (B.) burgdorferi sensu lato (s.l.) complex [1].
In Central Europe, B. burgdorferi, B. afzelii, B. garinii, B. spielmanii as
well as B. bavariensis are the causative agents of Lyme disease while
the pathogenic potential for B. valaisiana remains unclear [2–6].
There are several lines of evidence that B. valaisiana (formely
described as genomic groups VS116 and M19) might also cause
human Lyme disease even though only skin biopsies or
cerebrospinal fluid samples of erythema migrans, acrodermatits
chronica atrophicans, and neuroborreliosis patients were found to
be positive for B. valaisiana DNA [3,4]. Complement plays an
important role for the recognition, discrimination, and elimination
of invading microorganisms [7]. As a central part of the human
innate immune system, it is immediately activated upon entry of
an intruder via the alternative or the lectin pathways and also by
the classical pathway. Activation results in the cleavage of the
central component C3 and the generation of active splice
fragments C3a and C3b, and deposition of highly-reactive C3b
molecules on activator cell surfaces leads to opsonization followed
by opsonophagocytosis. In addition, progression of the cascade
and formation of the lytic membrane attack complex (MAC)
results in complement-mediated killing of the invading pathogen.
The potent complement regulators include C1 esterase inhibitor
(C1-Inh), a highly glycosylated molecule of approximately
105 kDa [8] which regulates the initial complement activation
steps of the classical and lectin pathways [9–11]. Interaction of C1-
Inh with C3b and factor B interferes with formation of the C3
convertase and thereby also prevents alternative pathway activa-
tion [11].
Factor H (CFH) and Factor H-like protein 1 (FHL1) are the key
inhibitors of the alternative pathway, both of which act as co-
factors for factor I-mediated inactivation of C3b to iC3b,
inhibiting the formation and accelerating the decay of the
C3bBb convertase, and finally competing with factor B for
binding to C3b [12–15]. CFH is composed of 20 individually
folding protein domains, termed short complement regulator
(SCR) [15]. The 42-kDa FHL1 protein consists of the seven N-
terminal SCRs of CFH, including the complement regulatory
domains and has a unique C-terminal extension of four
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Factor H-related proteins (CFHRs) all of which belong to the
human CFH family [16,17]. A common feature of these molecules
is the high degree of similarity of their C-terminal SCR domains of
CFH [16,18]. CFHR1 acts as a complement regulator by
inhibiting the assembly and membrane insertion of the terminal
membrane attack complex and inhibits C5 convertase activity [19]
while the biological function(s) of CFHR2 is as yet unclear.
The key fluid-phase complement regulator of the classical
pathway, C4Bp acts as cofactor for factor I-mediated degradation
of C4b to C4d and facilitates dissociation of C2a from the C3
convertase C4b2a of the classical pathway. By preventing
formation of the C3 convertase, the generation of C5b and
further downstream activation products in the cascade are
impeded [20,21].
Differences in host specificity largely correlate with the re-
sistance/sensitivity pattern of Lyme disease spirochetes to com-
plement and allow the various kinds of borreliae to selectively
survive in diverse mammalian hosts [22,23].
The most prominent complement evasion strategy used by
serum-resistant borreliae involves binding of host-derived fluid-
phase complement regulators CFH and FHL1 [24–27]. While
elucidating the molecular mechanisms of complement resistance,
two major groups of genetically and structurally unrelated
molecules, collectively termed complement regulator-acquiring
surface proteins (CRASPs) have been identified among serum-
resistant B. burgdorferi, B. afzelii, B. spielmanii, and B. bavariensis
isolates. These molecules represent ligands for CFH and FHL1 or
CFH, CFHR1, CFHR2, and CFHR5 [25,28–31]. The CFH/
FHL1-binding proteins consists of CspA (formerly referred to as
BBA68 or CRASP-1) of B. burgdorferi, B. afzelii, and B. spielmanii,
and CspZ (formerly referred to as BBH06 or CRASP-2) of B.
burgdorferi [31–34]. The CFH/CFHRs-binding proteins include
members of the Erp (OspE/F-related) protein family ErpP
(CRASP-3), ErpC (CRASP-4), ErpA (CRASP-5), OspE, and the
p21 protein [27,28,35–40]. It has also been shown that serum
resistance of B. burgdorferi directly correlates with the expression of
CspA or CspZ [41–43].
To extend our analysis on complement resistance of Lyme
disease spirochetes, we examined the serum susceptibility of three
B. valaisiana isolates derived from feeding or questing Ixodes ricinus
ticks. Here we show for the first time, that a particular B. valaisiana
strain resists complement-mediated killing. Interestingly, the
molecular mechanism of complement resistance differs from other
borrelial species in that it is independent of the recruitment of
complement regulators of the alternative (CFH, FHL1), classical
(C1-Inh, C4Bp) or Lectin pathways (C1-Inh) or degradation of key
complement components C3, C3b, C4, C4b and C5, suggesting
that certain spirochetes may have developed alternative strategies
to overcome innate immunity.
Materials and Methods
Ethics Statement
The study and the respective consent documents were approved
by the ethics committee at the Johann Wolfgang Goethe-
University of Frankfurt (control number 160/10). All healthy
blood donors provided written informed consent.
Bacterial Strains and Culture Conditions
Borrelial strains B. burgdorferi LW2 (skin isolate, Germany), B.
garinii G1 (CSF isolate, Germany), B. valaisiana Bv9 (tick isolate,
Germany), B. valaisiana ZWU3 Ny3 (tick isolate, Germany), and
type strain B. valaisiana VS116 (tick isolate, Switzerland) were
cultured until mid-exponential phase (5610
7 cells per ml) at
33uC in Barbour-Stoenner-Kelly (BSK-H) medium (Bio &
SELL, Feucht, Germany). Relapsing fever spirochete B. duttonii
strain LA1 was cultured at 33uC in BSK-H medium
supplemented with 3% of rabbit serum at 33uC. The density
of spirochetes was determined using dark-field microscopy and
a Kova counting chamber (Hycor Biomedical, Garden Grove,
CA).
Human Sera, Monoclonal and Polyclonal Antibodies, and
Human Serum Proteins
Normal human serum (NHS) used for serum susceptibility
testing and ligand affinity blotting or as a source of CFH was tested
for the presence of anti-Borrelia IgM and IgG antibodies by
commercially available ELISAs (EnzygnostH Borreliosis/IgM and
EnzygnostH Lyme link VlsE/IgG, Siemens Healthcare Diagnostics
Products GmbH, Marburg, Germany). Only sera proven to be
negative for IgM or IgG anti-Borrelia antibodies were used to form
the serum pool.
Purified human complement components CFH, C4b binding
protein (C4Bp), C1q esterase inhibitor (C1-Inh), C3, C3b, C4,
C4b, C5, and Factor I were purchased from Complement
Technology, Tyler, TX, USA. The cloning, expression, and
purification of FHL1 has been described previously [12].
Polyclonal goat anti-CFH antiserum (dilution 1/1,000), poly-
clonal anti-C4 antiserum (dilution 1/1,000) (recognizing the a-,
b-, and c-chain as well as the a4 fragment but not C4c and
C4d), goat anti-human C3 (dilution 1/1,000 for immunofluor-
escense microscopy and 1/2,000 for Western blotting) (recog-
nizing the a- and b-chain, the a68, a43 as well as the a41
fragment but not C3d) and C6 antibodies (dilution 1/50) were
purchased from Merck Biosciences, Bad Soden, Germany. The
polyclonal sheep anti-C4Bp antiserum (dilution 1/1,000) was
purchased from The Binding Site, Schwetzingen, Germany.
Polyclonal anti-C1-Inh antiserum (dilution 1/1,000), the poly-
clonal anti-C5 antibody (dilution 1/1,000) (recognizing the a-
and b-chain), and the monoclonal anti-human C5b-9 antibody
(dilution 1/10) were purchased from Quidel (San Diego, CA,
USA). Polyclonal rabbit anti-SCR1-4 antiserum was used for
detection of CFH and FHL1 [12]. Rabbit polyclonal anti-
CFHR1 antibody was used for detection of CFHR1 and
CFHR2 and CFHR5 [44].
Molecular Genotyping of Borrelial Isolates by Restriction
Fragment Length Polymorphism
Genotyping of borrelial isolates was performed by PCR
amplification of the ospA gene followed by restriction fragment
length polymorphism analysis as described by Michel et al. [45].
For differentiation, PCR-generated ospA fragments were digested
separately with 0.5 U of restriction endonucleases BglII, SspI,
HindIII (New England Biolabs, Frankfurt, Germany), Kpn21
(Fermentas, St. Leon-Rot, Germany), and SfuI (Roche Applied
Science, Mannheim, Germany) overnight according to the
manufacturers instruction. The digested PCR fragments were
then analyzed by electrophoresis on a 2% agarose gel and
visualized with ethidium bromide. Fragment size was determined
by comparison to DNA fragments of a 123 bp molecular standard
(Invitrogen, Karlsruhe, Germany). Genospecies’ designation of the
isolates was performed by analyzing the resulting genospecies-
specific PCR-RFLP patterns according to Michel et al. [45]. In
addition, amplicons generated were sequenced by the dideoxy
chain-termination method and the processed sequences were
subjected to BLAST search (http://blast.ncbi.nlm.nih.gov).
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Whole cell lysates obtained from each borrelial isolate (15 mg
per lane) were subjected to 10% tris/tricine SDS-PAGE under
reducing conditions and transferred to nitrocellulose as previously
described [30,44].
Serum Susceptibility Testing
Serum susceptibility of borrelial strains was assessed by employ-
ing a growth inhibition assay as previously described [46,47].
Briefly, highly motile spirochetes (1.25610
7) diluted in a final
volume of 100 ml in BSK medium containing 240 mgm l
21 phenol
red were incubated with 50% NHS or 50% heat-inactivated
human serum (hiNHS) in microtiter plates for 9 days at 33uC
(Costar, Cambridge, MA, USA). Growth of spirochetes was
monitored by measuring a color shift of the pH indicator in the
medium at 562/630 nm using an ELISA reader (PowerWave HT,
Bio-Tek Instruments, Winooski, VT, USA). The Gene 5 software
was used to calculate the growth curves (Bio-Tek Instruments,
Winooski, VT, USA).
Binding of Complement Proteins to Viable Spirochetes
Borreliae (2610
9 cells) grown to mid-log phase were gently
washed and resuspended in 750 ml NHS supplemented with
34 mM EDTA (pH 8.0) to avoid complement activation or 750 ml
hiNHS. After 1 h incubation at room temperature and four wash
steps with PBSA (0.15 M NaCl, 0.03 M phosphate, 0.02% sodium
azide, pH 7.2) containing 0.05% Tween-20, proteins bound to the
borrelial surface were eluted by incubation with 100 mM glycine-
HCl (pH 2.0) for 15 min. Cells were then removed by centrifu-
gation at 14.0006g for 10 min at 4uC, and the supernatant was
neutralized by adding 1 M Tris (pH 9.0). Both, the last wash and
the eluate fraction were separated by Laemmli-SDS-PAGE under
non-reducing conditions and binding of CFH, FHL1, CFHR1,
CFHR2, and CFHR5 was analyzed by Western blotting using
specific antisera [44]. For C4Bp detection, the samples were
separated by 10% tris/tricine SDS-PAGE under reducing
conditions.
Binding of Purified Complement Proteins to Spirochetes
by ELISA
Spirochetes grown to mid-log phase were gently washed and
resuspended in 500 ml Dulbecco’s PBS without Ca
2+ and Mg
2+.
Microtiter plates (Polysorb, Nunc, Roskilde, Denmark) were
coated with 5610
7 cells over night at 4uC. Microtiter plates were
washed threefold with PBS containing 0.05% Tween 20 and
treated for 1 h at RT with blocking buffer (Applichem GmbH,
Darmstadt, Germany). After washing, CFH or C4Bp (500 ng each
in a final volume of 100 ml) was added and incubated for 1 h at
RT. Thereafter, the wells were washed with PBS containing
0.05% Tween 20 (CFH and C4Bp) and bound CFH or C4Bp was
detected with either goat anti-CFH polyclonal antiserum or sheep
anti-C4Bp polyclonal antiserum, respectively. After washing,
bound proteins were identified using appropriate secondary
horseradish peroxidase–coupled antisera. Detection was per-
formed with 1,2-phenylenediamine dihydrochloride as substrate
(OPD, Sigma-Aldrich, Taufkirchen, Germany) and absorbance
was measured at 490 nm.
Determination of Intrinsic C3b and C4b Cleavage Activity
of Spirochetes
Proteolytic activity of borrelial cells was analyzed in the
presence and absence of complement regulators CFH and
C4Bp. Cells (5610
8) grown to mid-log phase were gently washed
and resuspended in either 100 ml hiNHS, 100 ml GVB
++-buffer
(Complement Technology, Tyler, TX, USA) containing 5 mg
CFH or 100 ml GVB
++-buffer containing 5 mg C4Bp, respectively.
After incubation for 60 min at room temperature, cells were
washed and resuspended in GVB
++-buffer containing C3b (1 mg/
ml) and Factor I (250 ng/ml) or C4b (1 mg/ml) and Factor I
(250 ng/ml), respectively. The reaction mixtures were incubated
for 60 min at 37 uC and cells were sedimented by centrifugation at
14.0006g for 10 min at 4uC. Each supernatant was then mixed
with sample buffer, subjected to SDS-PAGE under reducing
conditions and transferred onto a nitrocellulose membrane. C3b
and C4b degradation products were visualized by Western blotting
using a polyclonal goat anti-C3 antiserum or a polyclonal goat
anti-C4 antiserum.
Determination of Intrinsic C3, C4 and C5 Cleavage
Activity of Spirochetes
Spirochetes (5610
8) grown to mid-log phase were gently
washed and resuspended in 20 ml GVB
++-buffer (Complement
Technology, Tyler, TX, USA) containing 1 mg C3, 1 mgC 4o r
1 mg C5. After incubation for 60 min or 120 min at 37 uC with
gentle agitation, cells were sedimented by centrifugation at
14.0006g for 10 min at 4uC. Each supernatant was then mixed
with sample buffer, subjected to 10% tris/tricin SDS-PAGE
under reducing conditions and transferred onto a nitrocellulose
membrane. C3, C4 and C5 degradation products were
visualized by Western blotting using a polyclonal goat anti-C3
antiserum, a polyclonal goat anti-C4 antiserum or a polyclonal
goat anti-C5 antiserum.
Detection of Deposited Complement Components by
Immunofluorescence Microscopy
For detection of complement components deposited on the
borrelial surface after complement activation, an immunofluo-
rescence assay was performed as previously described [29,43].
In brief, spirochetes (6610
6) were incubated in 25% NHS or, as
a control, in 25% hiNHS for 30 min at 37uC with gentle
agitation. Ten microliters of cell suspension were spotted on
glass slides, allowed to air dry overnight, and fixed in methanol.
After 1 h incubation at 37uC with polyclonal antibodies directed
against the complement components C3, C4, and C6 or a mAb
directed against the membrane attack complex (MAC) slides
were washed and subsequently incubated with Alexa 488-
conjugated antibodies directed against either goat or mouse
antibodies (Molecular Probes, Eugene, OR, USA). After
washing, the slides were mounted with ProLong Gold antifade
reagent (Molecular Probes, Eugene, OR, USA) containing
DAPI.
Determination of the C3a and C4a Generation
Spirochetes (6610
6) grown to mid-log phase were gently washed
and resuspended in 100 ml sample dilution buffer containing 25 ml
NHS. After incubation for 5 min at 21uC (C3a) or for 5 min at
37uC (C4a), cells were sedimented by centrifugation at 14.0006g
for 10 min at 4uC. As a control, NHS was also pre-incubated for
5 min at 21uC and 37uC, respectively. Supernatants were then
diluted as recommend by the manufacturer and samples were
applied to microtiter plates containing immobilized monoclonal
antibodies against C3a and C4a, respectively. Generation of C3a
was analyzed by the MicroVue C3a Plus ELISA (Quidel, San
Diego, CA, USA) and for determination of C4a in NHS, the BD
OptEIA
TM Human C4a ELISA Kit (BD Biosciences, Heidelberg,
Germany) was used.
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Serum Susceptibility of B. valaisiana
To further evaluate the serum resistance pattern of B. valaisiana
to human complement, three isolates collected from ticks at
different geographical locations were incubated in 50% active
NHS or in 50% hiNHS for up to 9 days and cell growth was
monitored in a colorimetric growth survival assay [47,48]. Growth
of viable spirochetes results in a continuous decrease of the
absorbance values due to accumulation of secondary metabolites
in the BSK-H medium. As demonstrated in figure 1, growth of B.
valaisiana isolate Bv9, B. valaisiana type strain VS116, and serum-
sensitive control strain B. garinii G1 when challenged with 50%
NHS was completely inhibited as evidenced by only minor
changes of absorbance values. Under identical experimental
conditions, B. valaisiana ZWU3 Ny3 as well as serum-resistant B.
burgdorferi LW2 showed growth in NHS as indicated by continuous
decrease of absorbance values. As expected, hiNHS did not affect
growth of the five borrelial strains analyzed. In contrast to previous
findings, only B. valaisiana strain ZWU3 Ny3 resist complement-
mediated killing by human serum.
Deposition of Activated Complement Components on
the Surface of B. valaisiana
Next, we assessed deposition of activated complement
components C3, C6 and the membrane attack complex
(MAC) on the surface of B. valaisiana isolates Bv9, VS116,
and ZWU3 Ny3 as well as serum-resistant B. burgdorferi LW2
and serum-sensitive B. garinii G1. Complement C3, C4, C6 and
MAC (C5b-9) were strongly deposited on the surface of the
serum-sensitive B. valaisiana Bv9 and VS116 as well as on the
serum-sensitive control strain B. garinii G1 (Fig. 2). In contrast,
serum-resistant strains B. valaisiana ZWU3 Ny3 and B. burgdorferi
LW2 showed marginal or no fluorescent staining for all three
complement components analyzed, suggesting that the comple-
ment cascade was inhibited at the level of C3 and C4
activation. Slides were also counterstained with DAPI to identify
all spirochetes in a given field of view. Most of the complement-
positive spirochetes showed extensive bleb formation when
exposed to human serum, while a few cells stained negative for
complement but were positive in the DAPI stain. Those
spirochetes most likely represent ‘‘cell ghost’’ as previously
described for serum susceptible B. garinii and B. lusitaniae strains
[43,49]. When spirochetes were incubated with heat-inactivated
NHS, the cell morphology remained completely intact and
deposition of complement was not detectable by immunofluo-
rescence microscopy (data not shown). Thus, treatment of
spirochetes with active NHS leads to strong complement
activation followed by robust deposition of effector components
to B. valaisiana Bv9 and VS116 but not to serum-resistant isolate
ZWU3 Ny3.
Identification of CFH-binding Proteins in B. valaisiana
It is well-established that resistance of B. burgdorferi, B. afzelii,
and B. spielmanii to complement-mediated lysis directly correlates
with binding of complement regulators CFH and FHL1
[24,25,29,31,36]. For this reason, we sought to identify potential
CFH/FHL1-binding proteins produced by serum-resistant B.
valaisiana ZWU3 Ny3 using ligand affinity blotting. Whole cell
lysates obtained from all three B. valaisiana isolates and the two
control strains were separated by SDS-PAGE and proteins were
transferred to nitrocellulose membranes. Following incubation
Figure 1. Serum susceptibility testing of B. valaisiana. A colorimetric growth survival assay was used to investigate susceptibility to human
serum of B. valaisiana Bv9, VS116, ZWU3 Ny3, B. garinii G1, and B. burgdorferi LW2. Spirochetes were incubated in either 50% NHS (diamonds) or 50%
hiNHS (rectangles) over an incubation period of 9 days at 33uC. Color changes were monitored by measurement of the absorbance at 562/630 nm. All
experiments were performed three times with at least three replicates, obtaining very similar results. For clarity, data of a representative experiment
are shown. Error bars represent 6 SD.
doi:10.1371/journal.pone.0053659.g001
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antiserum, a very faint signal corresponding to a CFH-binding
protein of approximately 15 kDa could be detected within
serum-sensitive B. valaisiana isolate Bv9 and VS116 but not in
serum-resistant ZWU3 Ny3 (Fig. 3). Using a polyclonal anti-
CFHR1 antiserum, Bv9 but neither VS116 nor ZWU3 Ny3
showed a 15 kDa CFHR1-binding protein. For comparison,
a cell lysate obtained from serum-resistant B. burgdorferi LW2
showed four CFH-binding CRASP proteins (CspA, CspZ, ErpP,
and ErpA), three proteins that strongly bound CFHR-1 (CspA,
ErpP and ErpA) and two FHL1-binding proteins (CspA and
CspZ). Furthermore, FHL1-binding proteins could not be
detected within the three B. valaisiana isolates. In agreement
with our previous data, serum-sensitive B. garinii G1 did not
produce any CFH/FHL1-binding proteins under in vitro culti-
vation [25,29,43]. Taken together, distinct B. valaisiana isolates
are able to produce a 15 kDa protein that possesses potential
CFH/CFHR1-binding capability, but apparently did not
contribute to resistance to complement.
Identification of Complement Regulators Bound to the
Surface of Intact Borrelial Cells
Serum-resistant B. burgdorferi, B. afzelii, and B. spielmanii bind
complement regulators CFH and FHL1 to circumvent comple-
ment-mediated lysis [24,25,29]. To further examine whether B.
valaisiana is able to recruit complement regulators from human
serum, borrelial cells were incubated in NHS-EDTA (to avoid
complement activation) (Fig. 4). Following extensive washing,
bound proteins were eluted from the spirochetal surface using
0.1 M glycine-HCl (pH 2.0). The last wash and the final eluate
fraction were collected, separated by SDS-PAGE and subjected to
Western blotting using different polyclonal antisera for the
detection of complement regulators CFH, FHL1, CFHR1,
CFHR2, CFHR5, C4Bp, and C1-Inh. CFH and FHL1, the key
regulators of the alternative pathway could be detected in the
eluate fraction obtained from serum-resistant control strains B.
burgdorferi LW2 and B. duttonii LA1, but not in the appropriate
fractions of serum-sensitive B. valaisiana Bv9 and VS116 as well as
serum-resistant B. valaisiana ZWU3 Ny3. As expected, serum-
sensitive control strain B. garinii G1 did not bind CFH and FHL1
at all. Of note, the faint band above CFH detected represents
cross-reacting immunoglobulins derived from the BSK culture
medium.
CFH-binding proteins belonging to the Erp protein family, in
particular ErpA/CRASP-5, ErpC/CRASP-4, ErpP/CRASP-3
as well as OspE bound CFH only under denaturated conditions
in a solid phase assay (e.g. by using purified recombinant
proteins or borrelial cell lysates) but did not bind CFH when
the same proteins are exposed on the surface of viable cells
[44,50]. By contrast, these borrelial proteins bound strongly to
other members of the CFH protein family, namely CFHR1,
CFHR2 and to a lower extent to CFHR5. Elucidating binding
of CFHRs to B. valaisiana Bv9 and VS116 producing the
15 kDa CFH-binding protein, the wash and eluate fractions of
Figure 2. Determination of activated complement components on the surface of B. valaisiana. Complement components C3, C4, C6 and
MAC deposited on the surface of B. valaisiana isolates Bv9, VS116, ZWU3 Ny3, B. garinii G1, B. burgdorferi LW2 were visualized by indirect
immunofluorescence microscopy. Spirochetes were incubated with 25% NHS for 30 min at 37uC with gentle agitation and deposited C3, C4, C6, and
MAC were analyzed with specific antibodies against each component and appropriate Alexa 488-conjugated secondary antibodies. For visualization
of the spirochetes in a given microscopic field, the DNA-binding dye DAPI was used. The spirochetes were observed at a magnification of 1006
objective. The data were recorded with a DS-5Mc CCD camera (Nikon) mounted on an Olympus CX40 fluorescence microscope. Each panel is
representative of at least 20 microscope fields.
doi:10.1371/journal.pone.0053659.g002
Immune Evasion of Borrelia valaisiana
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e53659all borrelial isolates tested were also analyzed for CFHR1 and
CFHR2 (Fig. 4A). The two glycosylated forms of CFHR1
(CFHR1a and CFHR1b) were detected in the eluate fractions
of B. burgdorferi LW2 (this strain produced CFHR-binding
proteins ErpP and ErpA) as well as B. valaisiana Bv9, VS116,
and ZWU3 Ny3 but not in the eluate fraction of B. garinii G1.
Intriguingly, the binding patterns of the 15 kDa proteins of B.
valaisiana Bv9 and VS116 resemble the CFHR-binding Erp
proteins ErpA/CRASP-5 and ErpP/CRASP-3 of B. burgdorferi
LW2. Binding of CFHR2 and CFHR2a was only detected for
B. burgdorferi LW2 and B. valaisiana Bv9. Concerning the African
tick-borne relapsing fever spirochete B. duttonii LA1, binding of
CFHR1a and CFHR1b could be detected for this particular
borrelial strain.
Next, we sought to determine whether B. valaisiana is able to
bind C4Bp and/or C1-Inh as the key complement regulators of
the classical and lectin pathways. To this end, isolates were
incubated with NHS-EDTA (for C4Bp binding) or heat-
inactivated NHS (for C1-Inh binding). As demonstrated in
Figure 4, none of the Lyme disease spirochetes bound C4Bp or
C1-Inh to their surface. To exclude possible limitations of our
experimental setup, we also investigated B. duttonii LA1 known
to bind C4Bp and C1-Inh [51,52]. Employing identical
conditions for the serum adsorption assays, binding of C4Bp
and C1-Inh to strain LA1 could be clearly detected by Western
blotting (Figure 4A).
Interaction of spirochetes with CFH and C4Bp was also assessed
by ELISA as quantitative method for analyzing binding of distinct
complement regulators. Again, none of the B. valaisiana isolates
bound to purified CFH and C4Bp (Figures 4B and C, re-
spectively). In addition, binding of CFH and C4Bp to spirochetes
were also assessed under less stringent washing conditions. Again,
none of the B. valaisiana strains including ZWU3 Ny3 bound either
complement regulators (data not shown). This finding strongly
suggests that isolate ZWU3 Ny3 overcomes complement-mediated
killing by a different mechanism that is independent of binding of
host-derived complement regulators.
Determination of the Potential Intrinsic Proteolytic
Activity of B. valaisiana for Various Complement
Components
To clarify our somewhat paradoxical observation that serum-
resistant B. valaisiana ZWU3 Ny3 failed to bind any of the tested
complement regulators to its surface, a degradation assay was
employed to detect intrinsic proteolytic cleavage capacity of
spirochetes for C3b (Fig. 5). To this end, spirochetes were
incubated with or without purified CFH for 60 min. After
extensive washing, Factor I and C3b were added to each
reaction mixture and following incubation, the reaction mixtures
were separated by SDS-PAGE and C3b degradation products
were then analyzed by Western blotting. CFH bound to serum-
resistant B. burgdorferi LW2 retained its cofactor activity as
shown by the appearance of the characteristic cleavage pattern
of C3b (68 and 43 kDa a-chain). In contrast, C3b remained
intact when B. garinii G1 and B. valaisiana isolates Bv9, VS116
as well as ZWU3 Ny3 were investigated, in the presence or
absence of CFH as evidenced by the presence of the 110 kDa
achain and the 75 kDa b-chain (Fig. 5B). Thus, none of the B.
valaisiana isolates analyzed exhibit an intrinsic proteolytic activity
to allow inactivation of the complement component C3b. No
complement C3 cleavage products could be detected after
incubation with the respective borrelial strains, except for B.
burgdorferi LW2, showing a fragment that correspond to the
41 kDa achain (Figure S1).
Although all borrelial isolates examined were unable to bind
complement regulator C4Bp, we sought to determine whether
spirochetes, in particular B. valaisiana ZWU3 Ny3, are able to
cleave C4b in the absence of C4Bp. Thus, cells were incubated
with purified C4Bp from human serum, with NHS as a natural
source of C4Bp or in GVB
++ buffer for 60 min before being
extensively washed and subsequently purified C4b and purified
Factor I were added. To test for C4b degradation, a polyclonal
anti-C4 antibody was used that recognizes the 13 kDa a4
fragment, the 75 kDa b-chain as well as the 33 kDa c-chain
(Fig 6A). Cleavage of C4b, as detected by visualization of the
Figure 3. Identification of CRASPs among B. valaisiana. Cell lysates (30 mg each) obtained from control strains B. burgdorferi LW2 and B. garinii
G1 as well as from B. valaisiana isolates Bv9, VS116, and ZWU3 Ny3 were subjected to 10% tris/tricine SDS-PAGE and transferred to nitrocellulose. The
membranes were then incubated with either NHS as source for CFH and CFHR1 or with cell culture supernatant containing recombinant FHL1.
Potential CFH/FHL1/CFHR1-binding proteins were detected using a polyclonal anti-CFH serum, a polyclonal anti-CFHR1 serum or a polyclonal anti-
SCR1-4 antiserum. Monoclonal antibody L41 1C11 recognizing the FlaB protein was used to show equal loading of bacterial lysates. The identified
CRASP proteins, CspA, CspZ, ErpP, and ErpA of B. burgdorferi LW2, the CFH-binding protein of B. valaisiana Bv9 and VS116, and the CFHR1-binding
protein of B. valaisiana Bv9 are indicated on the right and the mobility of the marker proteins is indicated on the left.
doi:10.1371/journal.pone.0053659.g003
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positive control but was absent for the borrelial strains analyzed
(Fig. 6B). When incubated with C4b purified from human
serum alone, or in the absence of C4Bp, the 83 kDa achain
remained intact, using B. garinii G1, B. valaisiana Bv9, VS116,
and ZWU3 Ny3 cells (Fig. 6B). In addition, no degradation was
found after incubation of these strains with NHS or GVB
++
buffer (data not shown). Unexpectedly, a weak signal of the C4b
cleavage product corresponding to the a4 fragment was
detectable upon incubation of serum-resistant B. burgdorferi
LW2 with C4b and Factor I.
Investigating degradation of complement component C4, we
found that neither of the Lyme disease spirochetes tested, nor the
relapsing fever B. duttonii strain LA1 displayed any proteolytic
capacity to cleave C4 in either the presence or absence of Factor I
(Figure S1).
In order to test the inactivation capacity on complement
component C5, spirochetes were incubated with purified C5 for 60
and 120 min. After centrifugation, supernatants were subjected to
Figure 4. Binding of complement regulators to intact spirochetes. (A) Ligand affinity blotting was performed to detect binding of
complement regulators. B. burgdorferi LW2, B. garinii G1, B. valaisiana isolates Bv9, VS116, and ZWU3 Ny3 as well as B. duttonii LA1 were incubated in
NHS-EDTA to prevent complement activation, washed extensively, and bound proteins were eluted using 100 mM glycine-HCl (pH 2.0). Both the last
wash (W) and the eluate (E) fractions obtained from each strain were separated by 12.5% Laemmli-SDS-PAGE (detection of CFH, FHL1, FHR1, FHR2,
and C1-Inh) or by 10% tris/tricine SDS-PAGE (C4Bp detection) and transferred to nitrocellulose. Membranes were probed either with a polyclonal anti-
SCR1-4 antiserum for the detection of both CFH and FHL1, a polyclonal anti-CFHR1 antiserum for the detection of CFHR1 and CFHR2, a polyclonal
anti-C4Bp antiserum, or with a polyclonal anti-C1-Inh antiserum. Binding of CFH (B) or C4Bp (C) to spirochetes (5610
7 cells) was assessed by ELISA.
Bound CFH was detected with a polyclonal goat anti-CFH antiserum and C4Bp was detected with a polyclonal sheep anti-C4Bp antiserum. Data
represent means and SD from three separate experiments, each performed at least in triplicate. ***p,0.001; **p,0.01. Raw data were analyzed by
one-way ANOVA with post hoc Bonferroni correction.
doi:10.1371/journal.pone.0053659.g004
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blotting using a goat anti-C5 antibody. No degradation fragments
of the 118-kDa a-chain or of the 74-kDa b-chain were detected
indicating that spirochetes lacked proteolytic activity for the
cleavage of C5 (Fig. 7).
Next, to exclude proteolytic degradation of complement
components C3, C3b, C4, C4b, and C5 by secreted proteases
we also analyzed supernatants collected from late logarithmic
borrelial cultures. Spirochete-free supernatants were incubated
with 2 mg of purified complement components for 180 min at
37uC. After termination of the reaction, a portion of the reaction
mixtures were applied to SDS-PAGE and cleavage products were
detected by Western blotting. As shown in Figure S2, no
degradation fragments could be visualized, suggesting that
spirochetes did not secrete proteases into the culture medium.
Taken together, these findings strongly suggest that serum-
resistant B. valaisiana ZWU3 Ny3 displayed no intrinsic proteolytic
activity that would have resulted in inhibition of complement by
cleavage of C3, C3b, C4, C4b, and C5.
Determination of the C3a and C4a Generation by B.
valaisiana
To further evaluate the ability of serum-resistant B. burgdorferi
LW2 and B. valaisiana ZWU3 Ny3 to inhibit complement
activation at the level of C3 and C4 we sought to quantify the
generation of C3a and C4a after incubation of spirochetes with
human serum by ELISA. As demonstrated in figure 8, C3
activation was significantly reduced for B. burgdorferi LW2 (p-value
,0.001) as well as for B. valaisiana ZWU3 Ny3 (p-value 0.05) while,
in contrast, a stronger C3a generation could be detected for
serum-sensitive B. garinii G1 as well as B. valaisiana Bv9 and VS116.
Of note, pre-incubation of NHS for 5 min at 21uC resulted in
a somewhat higher C3a generation compared to untreated NHS
samples. Nevertheless, the data collected support the notion that
ZWU3 Ny3 inhibits C3 activation to some extent.
To investigate C4a generation, spirochetes were incubated with
2% or 25% human serum for 5 min at 37uC and C4a was
measured using ELISA. However, no significant differences could
be observed between the serum-resistant and serum-sensitive
strains analyzed (data not shown).
Figure 5. Determination of the C3b proteolytic activity of B. valaisiana. (A) Schematic representation of the a- and the b-chain of C3b and the
cleavage fragments of the a-chain generated by CFH and Factor I. (B) Degradation of C3b by an intrinsic proteolytic activity of borrelial cells (4610
7)
was analyzed by detection of characteristic cleavage fragments after incubation of spirochetes with (+) or without (2) purified CFH. B. burgdorferi
LW2, B. garinii G1, B. valaisiana isolates Bv9, VS116, and ZWU3 Ny3 were incubated with CFH for 60 min at room temperature. After extensive
washing with PBS, C3b (10 ng/ml) and Factor I (20 ng/ml) were added and the mixture was incubated for 30 min at 37uC. Subsequently, samples
were heated to 95uC for 5 min, subjected to 12.5% Laemmli-SDS-PAGE and transferred onto a nitrocellulose membrane. The C3b degradation
products were visualized by Western blotting using a polyclonal goat anti-human C3 antiserum. As a positive control, purified CFH (50 ng) was
incubated with C3b and Factor I, and as a negative control complement proteins were incubated in the absence of CFH. The mobility of the a’- and
the b-chain of C3b and the cleavage products of the a’-chain (a’-68 and a’-43) is indicated. (+) incubation with all complement proteins; (2)
incubation without CFH.
doi:10.1371/journal.pone.0053659.g005
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Recruitment of complement regulators of the alternative
pathway, CFH and FHL1 by serum-resistant B. burgdorferi, B.
afzelii, and B. spielmanii enable these spirochetes to inhibit
complement activation at the central step of the cascade (C3
level), and thereby overcome complement-mediated killing
[24,25,29,31,36]. Here, we demonstrate that B. valaisiana isolates
differ in their susceptibility to human serum. Similar to the
serum-sensitive B. garinii control strain G1, B. valaisiana isolate
Bv9 and B. valaisiana type strain VS116 strongly activate
complement and large amounts of complement components
were deposited on their surface, whereas isolate ZWU3 Ny3
resists complement-mediated killing and showed limited or no
deposition of destructive complement components. Irrespective
of whether they displayed a serum-sensitive or resistant
phenotype, all three B. valaisiana isolates acquired CFHR-1
and strain Bv9, in addition, also bound CFHR2 from human
serum. Despite binding of these complement regulators, Bv9
and VS116 failed to regulate complement activation, thus
permitting bacteriolysis as previously shown for B. lusitaniae [49].
More interestingly, isolate ZWU3 Ny3 bound neither comple-
ment regulators of the alternative pathway CFH and FHL1, nor
of the classical and lectin pathways, C4Bp and C1-Inh,
respectively. We also showed that none of the B. valaisiana
isolates displayed an intrinsic proteolytic capacity to inactivate
C3, C3b, C4, C4b, and C5. These findings strongly suggest that
B. valaisiana ZWU3 Ny3 resist complement-mediated killing by
a novel mechanism of immune evasion.
Figure 6. Determination of the C4b proteolytic activity of B. valaisiana. (A) Schematic representation of the a-, b-, and the c-chain of C4b and
the cleavage fragments of the a-chain generated by C4Bp and Factor I. (B) Degradation of C4b by an intrinsic proteolytic activity of borrelial cells
(5610
8) was analyzed by detection of characteristic cleavage fragments after incubation of spirochetes with (+) or without (2) purified C4Bp. B.
burgdorferi LW2, B. garinii G1, B. valaisiana isolates Bv9, VS116, and ZWU3 Ny3 were incubated with C4Bp for 60 min at room temperature. After
extensive washing with GVB
++, C4b (1 mg/ml) and Factor I (1 mg/ml) were added and the mixture was incubated for 120 min at 37uC. Subsequently,
the samples were heated to 95uC for 5 min, subjected to 10% tris/tricine SDS-PAGE and transferred onto a nitrocellulose membrane. The C4b
cleavage products were visualized by Western blotting using a polyclonal goat anti-human C4 antiserum. As a positive control, purified C4b (1 mg)
was incubated with C4Bp and Factor I, and as a negative control complement proteins were incubated in the absence of complement regulator
C4Bp. The mobility of the a’-, b’-, and c’-chain and the a’4 fragment is indicated. (+) incubation with all complement proteins; (2) incubation without
C4Bp.
doi:10.1371/journal.pone.0053659.g006
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sensu lato-complex exhibit a high diversity in their susceptibility
pattern to human complement [23,29,46,47,49,53–56]. Concern-
ing serum susceptibility of B. valaisiana, the isolates investigated so
far showed a serum-sensitive phenotype [53,56,57]. Due to the
fragmentary information available and the limited number of
isolates (n=5) tested so far, the question of whether this particular
genospecies, in general, exhibits a serum-sensitive phenotype, as
observed for B. garinii and B. lusitaniae [46,47,49,53,56], has not
been adequately addressed. Here, we show for the first time that
a particular isolate of B. valaisiana ZWU3 Ny3 may resist
complement-mediated killing even though the majority of isolates
are susceptible to human serum. Hence, it is tempting to speculate
that complement-resistant cells are protected from innate immune
defenses and qua argumentum e contrario can more efficiently establish
an infection and survive in the human host. Although B. valaisiana
has not been successfully isolated from patients yet, there is some
evidence that this particular genospecies is an, albeit infrequent,
cause of Lyme disease [3,4,6]. However, to which extent serum-
resistant B. valaisiana are responsible for establishing human
infections remains unclear and necessitates cultivation of this
particular genospecies from Lyme disease patients.
To evade complement-mediated killing, serum-resistant spir-
ochetes acquire complement regulators CFH and FHL1 which in
turn leads to an efficient inactivation of deposited C3b [24–
26,29,53,55]. In addition, no or inadequate binding of CFH and/
or FHL1 is correlated with an excess of complement activation
and deposition of harmful complement components on the
borrelial surface as demonstrated for B. garinii and B. lusitaniae
[24,46,47,49,53,56]. To our knowledge, binding of human
complement regulators to viable B. valaisiana cells has not been
reported so far, although a proposed CFH-binding protein has
recently been identified using cell lysates of isolate VS116 [58].
Here, we show for the first time that a member of the B. valaisiana
genospecies did not bind the key complement regulators of the
alternative, classical, and lectin pathways (CFH, FHL1, C4Bp as
well as C1-Inh) (Figure 4). Interestingly, all B. valaisiana isolates
were able to bind CFHR1 and isolate Bv9 also bound CFHR2,
irrespective of their serum susceptibility. More recently, we
showed that surface-bound CFHR1 and CFHR2 were insufficient
to completely prevent complement activation, and thus failed to
protect spirochetes from complement-mediated killing [44,49,50].
In line with this assumption, large amounts of C3, C4, C6 and
MAC were detectable on the spirochetal surface following
incubation of serum-sensitive B. valaisiana VS116 and Bv9 with
active human serum (Figure 2). In contrast, the majority of cells of
B. valaisiana ZWU3 Ny3 did not show strong deposition of lethal
complement components akin to the serum-resistant B. burgdorferi
control strain LW2, indicating that this particular isolate uses other
mechanisms to combat complement activation.
Figure 7. Determination of the C5 proteolytic activity of B. valaisiana. (A) Schematic representation of the a-, and b-chain of C5. (B)
Degradation of C5 by an intrinsic proteolytic activity of spirochetes (5610
8) was analyzed by detection of potential cleavage products after
incubation of cells with purified C5. B. burgdorferi LW2, B. garinii G1, B. valaisiana isolates Bv9, VS116, ZWU3 Ny3, and B. duttonii LA1 were incubated
with 1 mg C5 for 60 min and 120 min at 37uC. After centrifugation, supernatants were subjected to 10% tris/tricine SDS-PAGE and transferred onto
a nitrocellulose membrane. The C5 fragments were visualized by Western blotting using a polyclonal goat anti-human C5 antiserum. As a negative
control, purified C5 (1 mg) was incubated under the same conditions. The mobility of the 118 kDa a-chain and the 74 kDa b-chain is indicated.
doi:10.1371/journal.pone.0053659.g007
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valaisiana, we observed a complete loss of cell mobility after serum
incubation and excessive bleb formation for isolates VS116 and
Bv9, (Figure 1 and 2) which is in complete agreement with
previous findings showing that B. valaisiana is highly sensitive to
human complement [53,56]. In contrast, the serum-resistant
isolate B. valaisiana ZWU3 Ny3 and the control strain B. burgdorferi
LW2 showed continuous growth in human serum and limited
complement deposition on their surface. Our observation of the
borreliacidal effect of human complement on spirochetes is in
accordance with previous findings that serum-sensitive B.
valaisiana, B. garinii, and B. lusitaniae were strongly affected by
complement [47,49,56].
Serum resistance of spirochetes is primarily mediated by the
interaction of CFH and FHL1 with two distinct borrelial outer
surface proteins, namely CspA and CspZ [26–30,35,36]. Addi-
tionally, spirochetes that lack the CspA or CspZ encoding genes
through loss of the respective plasmids or by inactivation of the
cspA gene become serum-sensitive [41–43]. Binding of CFHR1
and CFHR2 also necessitates interacting ligands, which have
previously been identified to be ErpP (CRASP-3), ErpC (CRASP-
4) and ErpA (CRASP-5), all of which belong to the polymorphic
OspE protein family [28,30,44,50,59]. Due to the considerable
degree of identity between the C-terminal domains of CFHR1
(100 and 97%) and CFHR2 (89 and 61%) to the C-terminal SCRs
19 and 20 of CFH [16], ErpP (CRASP-3), ErpC (CRASP-4), ErpA
(CRASP-5) as well as OspE orthologs of B. burgdorferi also bind
complement regulator CFH [28]. Further analyses revealed that
whereas recombinant CRASP-3, CRASP-4, and CRASP-5 readily
bind CFH, the native proteins predominately interacted with
CFHR1 and CFHR2 and failed to bind CFH [44,50]. Employing
ligand affinity blotting, we identified potential CFH/CFHR1-
binding proteins of B. valaisiana isolates Bv9 and VS116 with an
estimated molecular weight of ,15 kDa (Figure 3) which in regard
to their CFH/CFHR1-binding capabilities strongly resemble the
OspE orthologs of B. lusitaniae and B. spielmanii, as well as
a ,17 kDa protein recently described for B. valaisiana VS116
[49,58,60]. While the denaturated ,17 kDa protein of B. valaisiana
VS116 described by Bhide et al. [58] potentially bind CFH in
a ligand affinity blot, the authors did not analyzed binding of CFH
to viable spirochetes, strongly suggesting that the native protein
displays a different binding capability to this complement
regulator. In conclusion, it is apparent, that the findings from
our binding analysis with viable cells better serve to explain the
serum susceptible phenotype of a given borrelial isolate than do
conclusions based on ligand affinity blots.
Pathogenic microorganisms develop different strategies to
counteract complement [61–64]. Apart from the acquisition of
CFH and FHL1, Lyme disease spirochetes appear to bind the
negative regulator of the classical pathway, C4Bp [65]. Employing
different methodologies and conditions, we were unable to detect
binding of this regulator to B. valaisiana, B. burgdorferi, and B. garinii
(Figure 4). Under identical experimental conditions, binding of
C4Bp could be demonstrated for the relapsing fever B. duttonii
strain LA1 which is in line with previously published data [52,66].
However, binding of C4Bp failed to protect serum-sensitive B.
garinii from the destructive attack of complement, thus the
biological impact of the interaction of this regulator with Lyme
disease spirochetes for complement evasion is elusive.
Serum-resistant B. valaisiana ZWU3 Ny3 deposited limited
amounts of C3 and C4 on the surface (Figure 2) suggesting that
complement activation was influenced at very early steps of the
cascade. Complement inhibition should be accompanied by
a reduced release of potent bioactive mediators C3a and C4a
upon activation. The activation assays investigated (Figure 8)
showed a statistically significant reduction of C3 activation upon
pre-incubation of NHS with serum-resistant B. valaisiana ZWU3-
Ny3 (p-value,0.05) and serum-resistant B. burgdorferi LW2 (p-
value ,0.001) while no reduction could be observed concerning
the generation of C4a. The high amount of C4a generated by pre-
incubation of NHS might account for the similar C4a values
calculated for all borrelial strains and, seemingly, did not mirror
Figure 8. Determination of the C3a generation by B. valaisiana. Spirochetes (6610
6) were incubated with 25% of NHS for 5 min at 21uC and
activation of C3 was then analyzed by the MicroVue C3a Plus ELISA. Generated C3a was detected using a monoclonal anti-C3a capture antibody and
a HRP-conjugated polyclonal anti-C3 antiserum. All experiments were performed three times with at least three replicates, obtaining very similar
results. For clarity, data of a representative experiment are shown. Error bars represent 6 SD. Raw data were analyzed by one-way ANOVA with post
hoc Bonferroni correction. ***p,0.001; *p,0.05.
doi:10.1371/journal.pone.0053659.g008
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light of these experiments it is not entirely clear how this particular
B. valaisiana strain negatively influences complement activation at
the level of C4.
Excluding CFH, FHL1, and C4Bp as potential interacting
molecules responsible for mediating serum resistance of ZWU3
Ny3, we also investigated binding of C1-Inh as an additional
promising candidate. By analyzing binding of serum-derived
regulators, we detected binding of C1-Inh exclusively to the tick-
borne relapsing fever B. duttonii strain LA1, but not to Lyme
disease spirochetes, including isolate ZWU3 Ny3 (Figure 4),
indicating that this specific isolate exerts different means to resist
complement-mediated killing.
Concerning degradation of key complement components,
diverse microorganisms secrete to inactivate complement [67–
71]. Investigating degradation of C3, C3b, C4, C4b as well as C5,
none of the key components of the complement cascade were
cleaved by serum-resistant B. valaisiana ZWU3 Ny3 or could be
detected in the supernatant of this strain (Figures 5, 6, and 7, and
Figures S1 and S2), suggesting that this isolate lacks potent
proteolytic enzymes to inactivate complement.
In conclusion, we demonstrated that B. valaisiana isolates differ
in their susceptibility to human serum, thus providing some
evidence that in particular serum-resistant isolates might cause
Lyme disease. Contrary to our expectations, certain B. valaisiana
isolates appear to possess different molecular mechanism(s) to
inhibit complement activation, independently of the recruitment of
complement regulators or by inactivation of central complement
components. Even though that we are currently unable to
decipher the precise molecular mechanism, it is tempting to
speculate that B. valaisiana ZWU3 Ny3 expresses an outer surface
protein that directly interacts with components of the complement
system to inhibit complement activation. Further investigation is
required to identify potential complement inhibitory protein(s) of
this particular borrelial strain.
Supporting Information
Figure S1 Determination of the C3 and C4 proteolytic
activity of B. valaisiana. Degradation of C3 (A) and C4 (B) by
an intrinsic proteolytic activity of borrelial cells (5610
8) was
analyzed by detection of characteristic cleavage fragments after
incubation of spirochetes. B. burgdorferi LW2, B. garinii G1, B.
valaisiana isolates Bv9, VS116, and ZWU3 Ny3 were incubated
with C3 or C4 for 120 min at 37uC. Subsequently, the samples
were heated to 95uC for 5 min, subjected to 10% tris/tricine SDS-
PAGE under reducing conditions. The C3 and C4 cleavage
products were visualized by Western blotting using a polyclonal
goat anti-human C3 and a polyclonal goat anti-human C4
antiserum, respectively. As a control, purified C3 or C4 (1 mg
each) were incubated under identical conditions. The mobility of
the C3 and C4 cleavage fragments are indicated and the mobility
of the protein standard is indicated on the left. The mobility of the
marker proteins is indicated on the left.
(TIF)
Figure S2 Determination of complement degradation
by external proteases. Supernatants obtained from late
logarithmic cultures (10 ml each), as well as BSK medium (negative
control) were incubated with 2 mg of purified complement
components for 180 min at 37 uC. As a further control, purified
C3, C3b, C4, C4b, and C5 were incubated under identical
conditions.The reaction mixtures were terminated by adding SDS
sample buffer and one fourth of the reactions were subjected to
10% tris/tricin SDS-PAGE under reducing conditions. After
transfer to nitrocellulose membranes, complement components
were detected by using the appropriate polyclonal antisera as
described in the Material & Method section. The mobility of the
marker proteins is indicated on the left. For detection of
complement components in culture medium, same amounts of
BSK were subjected to 10% tris/tricine SDS-PAGE and proteins
were transferred to nitrocellulose membranes. Complement
components were then detected using appropriate polyclonal
antibodies. The mobility of marker proteins is indicated on the left.
(TIF)
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